Moderna Starts New COVID-19 Vaccine Trial by Angela Mohan on March 17, 2021 at 2:17 PM
First participants have been dosed in the Phase 1 study of mRNA-1283, Moderna s next generation COVID-19 vaccine candidate, which will assess the safety and immunogenicity of mRNA-1283. We are pleased to begin this Phase 1 study of our next generation COVID-19 vaccine candidate, mRNA-1283, said Stéphane Bancel, Chief Executive Officer of Moderna. Our investments in our mRNA platform have enabled us to develop this next generation vaccine candidate, which is a potential refrigerator-stable vaccine that could facilitate easier distribution and administration in a wider range of settings, including potentially for developing countries, Bancel added.